- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00658931
Cymbalta for Depression as a Complication of Bereavement
The primary objective of this pilot project is to evaluate the efficacy of Cymbalta for bereavement-associated depression. Participating patients will be treated with Cymbalta in doses up to 60mg daily for eight (8) weeks. The primary outcome measure for this study will be the 17-item Hamilton Rating Scale for Depression (HRSD-17). In pursuit of this objective, we will test the following hypothesis: After eight weeks of open-label treatment with Cymbalta for bereavement-associated depression, at least half of the participants will achieve remission, as measured by a score of 7 or less on the HRSD-17.
Secondary objectives of this project are:
- To determine the tolerability of Cymbalta treatment among patients with bereavement-associated depression (as measured by adverse events and the proportion of participants who discontinue Cymbalta before completing eight weeks of study treatment);
- To determine the effect of Cymbalta treatment on grief in patients with bereavement-associated depression (as measured by the Texas Revised Inventory of Grief and the Inventory of Complicated Grief after eight weeks of treatment compared to baseline); and
- To determine the effect of Cymbalta treatment on health status, pain, and other co-morbid symptoms in patients with bereavement-associated depression (as measured by the Edmonton Symptom Assessment System and the Medical Outcomes Study 12-item Short Form Health Survey administered at Weeks 2, 4, and 8 and compared to baseline).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this pilot project is to evaluate the efficacy of Cymbalta for bereavement-associated depression. Participating patients will be treated with Cymbalta in doses up to 60mg daily for eight (8) weeks. The primary outcome measure for this study will be the 17-item Hamilton Rating Scale for Depression (HRSD-17). In pursuit of this objective, we will test the following hypothesis: After eight weeks of open-label treatment with Cymbalta for bereavement-associated depression, at least half of the participants will achieve remission, as measured by a score of 7 or less on the HRSD-17.
Secondary objectives of this project are:
- To determine the tolerability of Cymbalta treatment among patients with bereavement-associated depression (as measured by adverse events and the proportion of participants who discontinue Cymbalta before completing eight weeks of study treatment);
- To determine the effect of Cymbalta treatment on grief in patients with bereavement-associated depression (as measured by the Texas Revised Inventory of Grief and the Inventory of Complicated Grief after eight weeks of treatment compared to baseline); and
- To determine the effect of Cymbalta treatment on health status, pain, and other co-morbid symptoms in patients with bereavement-associated depression (as measured by the Edmonton Symptom Assessment System and the Medical Outcomes Study 12-item Short Form Health Survey administered at Weeks 2, 4, and 8 and compared to baseline).
This pilot study is an eight-week, open-label clinical antidepressant treatment trial using Cymbalta (duloxetine hydrochloride) in doses between 20mg and 60mg daily for patients with co-morbid depression and bereavement. Twenty (20) patients who have sustained the loss of a first-degree relative (spouse, child, parent, or sibling) within the past two years AND meet criteria for a major depressive episode at the time of screening will be recruited for participation in this study. Patients who tolerate and respond to Cymbalta treatment will be offered maintenance therapy with Cymbalta for up to one year at the effective dose. We expect that Cymbalta treatment will be associated with substantial remission and response rates, as measured by HRSD-17 scores. Similarly, we expect substantial mean reductions in measures of grief and bereavement, with improvements in measures of pain, symptom burden, and functional status.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Jefferson Clinic, PC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Must have sustained the loss of a first-degree relative (spouse, partner, child, parent, sibling, or person otherwise described by the patient as a first-degree relative) within the past two years and one of the two following features must also be present:
- at least two months must have passed since the death prior to enrollment in the study, OR
- there must be evidence of marked functional impairment (as defined in the DSM-IV description of Bereavement, v62.82);
- Must meet criteria for a major depressive episode as defined in DSM-IV;
- Onset of this depressive episode must have occurred after the death of the first-degree relative (if the relative's death was unexpected) OR no more then three months prior to the death of the relative (if the relative's death was expected);
- HRSD-17 score of >17 at baseline assessment;
- Must be in stable medical health;
- Must be able to communicate in English; AND
- Must be willing and able to travel to the Cooper Green Mercy Hospital or the Jefferson Clinic, PC for evaluations according to the study protocol.
Exclusion Criteria:
- History of Dysthymic Disorder or a depressive episode preceding the death of the first-degree relative by more than three months;
- History or symptoms of mania or psychosis (e.g., bipolar disorders, schizophrenia and other psychotic disorders);
- Evidence of current alcohol or other substance abuse or dependence;
- Evidence of clinically significant dementia or cognitive impairment (from history or a score on the screening Mini Mental State Exam of 23 or less);
- Concomitant use of other antidepressants (patients can be enrolled after taper and clearance of other antidepressant medications);
- Concomitant use of medications known to have potential for clinically significant interaction with Cymbalta (patients can be enrolled after taper and clearance of other medications, if other medications can be safely discontinued).
- Suicidal thoughts with intent or plan, or other situations where the patient is judged to be a high risk of suicide;
- Known hypersensitivity to Cymbalta or any of its inactive ingredients;
- Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug; OR
Any of the following medical conditions present:
- Hepatic impairment or insufficiency,
- Hyponatremia,
- Narrow-angle glaucoma,
- History of seizures,
- Unstable hypertension, OR
- Pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
|
Drug treatment with Cymbalta
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
17-item Hamilton Rating Scale for Depression (HRSD-17)
Time Frame: Eight weeks
|
Eight weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Texas Revised Inventory of Grief (TRIG)
Time Frame: Eight weeks
|
Eight weeks
|
Prolonged Grief Disorder (PG-13) Measure
Time Frame: Eight weeks
|
Eight weeks
|
Clinical Global Impressions - Severity of Illness (CGI-S)
Time Frame: Eight weeks
|
Eight weeks
|
Clinical Global Impressions - Improvement (CGI-I)
Time Frame: Eight weeks
|
Eight weeks
|
Mini-Mental State Examination (MMSE)
Time Frame: Eight weeks
|
Eight weeks
|
Edmonton Symptom Assessment System (ESAS)
Time Frame: Eight weeks
|
Eight weeks
|
Medical Outcomes Study 12-item Short Form Health Survey (SF-12v2):
Time Frame: Eight weeks
|
Eight weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John L Shuster, MD, Jefferson Clinic, PC
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- FIJ-US-X047
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Drug treatment with Cymbalta
-
CelltrionCompletedHealth, SubjectiveKorea, Republic of
-
Skane University HospitalCompletedVascular Diseases
-
Institut Cancerologie de l'OuestFondation ARC; University of Angers, GRANEMUnknownStage III Renal Cell Cancer | Metastatic Renal CancerFrance
-
University Children's Hospital BaselPermamed AG, Switzerland; Galvita AG, SwitzerlandCompleted
-
Spectranetics CorporationCompletedPeripheral Artery DiseaseNew Zealand
-
Medical University of South CarolinaWayne State University; National Institute on Minority Health and Health Disparities... and other collaboratorsCompleted
-
Chinese University of Hong KongNot yet recruitingClinical Outcomes
-
Shanghai HEP Pharmaceutical Co., Ltd.CompletedHepatitis B, ChronicChina
-
Shanghai HEP Pharmaceutical Co., Ltd.Completed
-
Instituto BernabeuRecruiting